Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors
Myeloid Therapeutics
Myeloid Therapeutics
Incyte Corporation
Novartis
Avenzo Therapeutics, Inc.
Pfizer
Nurix Therapeutics, Inc.
Xencor, Inc.
858 Therapeutics, Inc.
Lyell Immunopharma, Inc.
Lyell Immunopharma, Inc.
Dana-Farber Cancer Institute
Instituto do Cancer do Estado de São Paulo
Klus Pharma Inc.
Theratechnologies
University of Washington
Exelixis
University Health Network, Toronto
Pfizer
Stanford University
Northwestern University
Cybrexa Therapeutics
Carisma Therapeutics Inc
Light Chain Bioscience - Novimmune SA
Salubris Biotherapeutics Inc
Valerio Therapeutics
Eli Lilly and Company
BioEclipse Therapeutics
Multitude Therapeutics Inc.
Pfizer
Canadian Cancer Trials Group
Eastern Cooperative Oncology Group
Xencor, Inc.
Corcept Therapeutics
MacroGenics
Gilead Sciences
Abramson Cancer Center at Penn Medicine
Vanderbilt-Ingram Cancer Center
City of Hope Medical Center
Swiss Cancer Institute
University of Washington
Alliance for Clinical Trials in Oncology
Pfizer
Peking Union Medical College Hospital
Albert Einstein College of Medicine
University of Chicago
Vanderbilt-Ingram Cancer Center
Wake Forest University Health Sciences
Ohio State University Comprehensive Cancer Center
Masonic Cancer Center, University of Minnesota
University of Washington